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Hjemdahl et al opine that the high rate of major bleeding in RE-LY patients assigned to dabigatran 150 mg twice daily who had interruption for >72 hours before surgery suggests accumulation of dabigatran in patients with renal impairment. However, data from RE-LY do not support this interpretation, because the same pattern of bleeding based on the timing of study drug interruption was seen in the subgroup of patients with an estimated creatinine clearance of <60 mL/ min. Instead, we believe that the results reflect the selection of longer interruption of dabigatran in patients at higher risk of bleeding.
David et al suggest that the rate of bleeding among warfarintreated patients requiring emergency surgery in RE-LY is higher than observed in Europe; however, the Mayo Clinic study they cite reported a 1% to 3% bleeding rate in patients undergoing elective surgery, 2 similar to the rate for comparable RE-LY patients. 1 David et al also refer to increased bleeding among patients undergoing catheter ablation for atrial fibrillation who were treated with dabigatran. 3 However, this was an observational study in which dabigatran was held on the morning of the procedure, whereas warfarin was continued; thus, the relative hazards of interrupted compared with maintained anticoagulation could explain these findings. 4 The assertion by David et al that there is a "clear advantage" to vitamin K antagonists in the setting of emergency surgery is not supported by data and is clearly refuted by the evidence from the RE-LY trial.
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